Semaglutide
Generic Name: semaglutide
Brand Names:
Ozempic, Wegovy, Rybelsus
Semaglutide is a GLP-1 receptor agonist used for type 2 diabetes and chronic weight management.
Overview
Semaglutide is a GLP-1 receptor agonist used for type 2 diabetes and chronic weight management.
Uses
Type 2 diabetes mellitus, chronic weight management in adults with obesity.
Dosage
Ozempic: Start 0.25 mg weekly, escalate to 0.5 mg then 1–2 mg weekly.
Side Effects
Common: Nausea, vomiting, diarrhea, constipation, decreased appetite.
Interactions
Insulin and sulfonylureas — increased hypoglycemia risk. May affect oral medication absorption.
Warnings
FDA Black Box Warning: Thyroid C-cell tumors in animal studies. Monitor for pancreatitis.
Pregnancy
Not recommended — discontinue at least 2 months before planned pregnancy.
Storage
Injection pens: Refrigerate before first use. After first use, room temperature up to 56 days.
Frequently Asked Questions
What is Semaglutide used for?▼
Type 2 diabetes mellitus, chronic weight management in adults with obesity.
What are the side effects of Semaglutide?▼
Common: Nausea, vomiting, diarrhea, constipation, decreased appetite.
Can I take Semaglutide during pregnancy?▼
Not recommended — discontinue at least 2 months before planned pregnancy.
What are the important warnings for Semaglutide?▼
FDA Black Box Warning: Thyroid C-cell tumors in animal studies. Monitor for pancreatitis.
Related Medications
Bath And Body Works Spf 35 Summer Crush Lip Balm
bath and body works spf 35 summer crush lip balm
Avobenzone - Sunscreen Octisalate - Sunscreen Homosalate - Sunscreen
Acetaminophen, Dextromethorphan Hbr, Doxylamine Succinate, Phenylephrine Hcl Tablet, Film Coated
acetaminophen, dextromethorphan hbr, doxylamine succinate, phenylephrine hcl tablet, film coated
Purpose Purpose Pain reliever/fever reducer Cough suppressant Antihistamine Nasal decongestant
Pertuzumab
pertuzumab
HER2/neu Receptor Antagonist [EPC]
11 DESCRIPTION Pertuzumab is a recombinant humanized monoclonal antibody and HER2/neu receptor antagonist that targets the extracellular dimerization domain (Subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). Pertuzumab is produced by recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary) culture. Pertuzumab has an approximate molecular weight of 148 kDa.
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.